ImmunityBio (IBRX) Projected to Post Earnings on Tuesday

ImmunityBio (NASDAQ:IBRX) is expected to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $31.8820 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 7:00 AM ET.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). The firm had revenue of $26.43 million for the quarter, compared to the consensus estimate of $21.95 million. On average, analysts expect ImmunityBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ImmunityBio Trading Down 2.4%

Shares of IBRX traded down $0.06 during midday trading on Tuesday, reaching $2.21. 1,167,824 shares of the stock were exchanged, compared to its average volume of 8,267,713. ImmunityBio has a 52 week low of $1.83 and a 52 week high of $5.88. The company’s 50 day moving average is $2.50 and its two-hundred day moving average is $2.59. The company has a market capitalization of $2.17 billion, a P/E ratio of -4.59 and a beta of 0.29.

Institutional Investors Weigh In On ImmunityBio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IBRX. Osaic Holdings Inc. boosted its position in shares of ImmunityBio by 32.3% during the 2nd quarter. Osaic Holdings Inc. now owns 201,759 shares of the company’s stock worth $533,000 after acquiring an additional 49,234 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in shares of ImmunityBio in the 2nd quarter valued at about $298,000. Tower Research Capital LLC TRC lifted its holdings in shares of ImmunityBio by 181.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 16,922 shares of the company’s stock valued at $45,000 after purchasing an additional 10,912 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of ImmunityBio in the 2nd quarter valued at about $91,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of ImmunityBio in the 2nd quarter valued at about $35,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research report on Tuesday, October 14th. D. Boral Capital restated a “buy” rating and set a $24.00 price objective on shares of ImmunityBio in a research note on Monday, September 8th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of ImmunityBio in a research note on Wednesday, September 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $10.75.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.